SICHUAN HEXIE SHUANGMA CO.,Ltd
四川双马
000935
Shenzhen Stock Exchange
Company Profile
1.Core Competencies Related to Biopharmaceutical R&D and Manufacturing Business （1）A well-established R&D system with profound expertise in peptide technology development （2）The core product portfolio is robust, with comprehensive coverage in the peptide pharmaceuticals and cosmetic peptide sectors, enabling business synergy （3） Leading production capacity with significant advantages in full-chain services （4）Advanced EHS, GMP management systems, and IP protection frameworks lay the foundation for sustainable development （5）The core team possesses extensive industry experience, building sustainable competitive advantages 2. Core Competencies Related to Building Materials Manufacturing Business （1） Quality and Brand Advantages （2） Industrial Advantages （3）Safety and Environmental Advantages （4）Technological Innovation Advantage 3. Core Competitiveness Related to Private Equity Fund Management Business （1）The company boasts a high-caliber, professional, seasoned, and stable investment management team, with most of its investment personnel originating from specialized investment institutions. These individuals possess extensive industry investment experience. Through years of dedicated effort, the investment team has accumulated profound industry resources and rich investment expertise, enabling them to collaborate effectively and make timely, sound professional judgments in complex and challenging market environments. （2）The company has established a mature and comprehensive investment management system, forming a systematic research approach to industries and markets, including top-down and bottom-up studies, as well as in-depth research on niche industries, leading companies, and emerging fields, ensuring thorough coverage of core investment areas. Additionally, the company has developed a complete due diligence framework covering business, financial, and legal aspects, with a dedicated and experienced internal due diligence team. It has implemented strict due diligence procedures and enables multi-level cross-checks between internal and external due diligence processes. （3）The company is equipped with a dedicated post-investment team and a mature post-investment management system. Post-investment managers continuously monitor the operational status of invested enterprises, implementing unified management over performance fulfillment, financial conditions, and operational management. They conduct regular tracking, monitoring, and evaluation of investment projects. Additionally, the company possesses profound industry insights, enabling it to integrate capital market resources, empower invested enterprises, provide diversified value-added services, and enhance the value of invested enterprises. （4）The company's investment management team possesses extensive experience in the capital market, is well-versed in various exit routes such as IPOs and M&A, and stays updated on the latest regulatory requirements. They can flexibly select exit timing and pathways based on the business model, development stage, and management approach of the invested projects, striving to maximize investment returns. The company actively conducts policy research and closely aligns its investments with national development strategies. （5）The company boasts a mature investor relations framework. It maintains close communication with fund investors, ensuring smooth progress in capital contributions. By establishing strong ties with domestic financial institutions, local state-owned enterprises, insurance funds, and capital from large corporations, the company has garnered widespread recognition for its private equity investment management capabilities and investment philosophy, providing a robust foundation for its investment operations. With a powerful resource network, the company has cultivated long-term, amicable partnerships with industry elites, outstanding entrepreneurs, sector experts, and portfolio companies.Through investment projects, a rich corporate ecosystem has been formed in the company's key investment areas. The corporate ecosystem and entrepreneurial resources provide powerful assistance for the company to deeply layout industry investments and accurately judge enterprise value.
Full description
Sichuan Shuangma, as a listed company engaged in industrial investment and management as well as private equity fund management, currently manages assets primarily including biopharmaceutical R&D and manufacturing enterprises, building materials production and manufacturing enterprises, and private equity fund management companies. Established in 1998, Sichuan Shuangma was listed on the main board of the Shenzhen Stock Exchange in August 1999 with the stock code 000935, serving as a constituent of indices such as the Shenzhen Component Index and the Shenzhen Select Index. The company's biopharmaceutical R&D and manufacturing business specializes in the research, development, and production of peptide products, featuring a comprehensive and efficient peptide R&D, production, and sales system. It offers full-cycle peptide product industrialization services, with core operations including peptide API R&D and production, peptide contract development and manufacturing (CDMO), and beauty peptide R&D and production. In the peptide API sector, the company focuses on chronic disease areas, prioritizing key products such as semaglutide, liraglutide, and tirzepatide, backed by profound technical reserves and mature, stable manufacturing processes. Currently, its core APIs have completed registration and filing in major global pharmaceutical markets, with continuously upgraded global supply capabilities and an international sales network, enabling stable and reliable high-quality product supply to global clients. Leveraging accumulated technical expertise and global compliance experience in the API field, the company has also established a full-chain peptide CDMO service system spanning early-stage R&D, process development to commercial production. With a mature R&D platform, scalable production capacity, and extensive global registration experience, it delivers efficient, compliant integrated solutions tailored to clients' needs across preclinical to commercial stages, earning widespread recognition for professional service capabilities. In the beauty peptide business, the company possesses over 100 beauty peptide APIs and high-value-added formulated liquid beauty peptide products. Through long-term collaborations with leading global cosmetic enterprises, it consistently enhances client product innovation and market competitiveness. In terms of production capacity, the company's API manufacturing base in Hubei (Hubei Jianxiang) has achieved an annual peptide API output exceeding 4 tons, with a maximum single batch production capacity of 100 kg. Notably, GLP-1 API output reaches 2 tons annually, with a single batch production capacity of 20 kg, and is projected to scale to 10 tons by mid-2026. Meanwhile, its formulation manufacturing base in Shenzhen (Shenzhen Jianxiang Kassette Bottle) boasts an annual production capacity of 10 million vials for kassette bottles, 15 million vials for water-filled glass vials, and 5 million vials for lyophilized powder injections. Moving forward, Shenzhen Jianyuan will continue to focus on the peptide core business, prioritizing technological iteration and production capacity optimization to deepen global market penetration, solidify and elevate its industry-leading position, and provide critical support for the company's overall strategy implementation and performance growth. The biopharmaceutical funds in which the company participates adopt a venture capital strategy, focusing on cutting-edge sectors such as new drug R&D and biotechnology. Through a specialized incubation model, they cultivate high-quality enterprises with broad growth prospects and significant potential in the field, driving the industry toward deeper and more specialized segments. This approach secures partners for the company's biopharmaceutical business, fostering a synergistic industrial ecosystem and a virtuous cycle. It continuously strengthens the collaborative effects of the industrial chain, injecting new momentum and forging new advantages for the company's high-quality development, further ensuring long-term sustainable growth and steady expansion of its business. The company's building materials production and manufacturing business includes products such as cement, clinker, and aggregates, which are widely used in infrastructure construction (e.g., railways, highways, water conservancy projects), municipal and public welfare projects (e.g., urban roads, public facilities), commercial housing development, industrial park construction, urban renewal and upgrading, and rural revitalization. The company's building materials production base is located in Yibin City, which provides significant locational advantages and industrial opportunities for the company's development. In recent years, leveraging its unique geographical advantages, profound cultural heritage, and vibrant industrial vitality, Yibin City is accelerating its transformation into a green, low-carbon development pioneer in the Yangtze River's upper reaches. Benefiting from the continuous advancement of the Chengdu-Chongqing Twin-City Economic Circle, Yibin City and its surrounding areas are upgrading and accelerating their transportation infrastructure, with multiple highways set to commence construction. Additionally, Yibin City is building a university town and a sci-tech innovation hub around its distinctive advantageous industries, supported by talent, technology, finance, and services to develop industrial clusters such as intelligent manufacturing, providing solid support and extensive market space for the company's building materials production and manufacturing business. In this business, the annual cement production capacity is 2 million tons, and the annual aggregate production capacity is 5 million tons. The private equity investment fund management company Xizang Jinhua primarily employs a market-oriented equity investment management and operation model to identify, invest in, cultivate, and empower high-quality assets. Its investment directions include but are not limited to internet, health, advanced manufacturing, cross-border e-commerce, new energy, consumption, and services. The investment focus of Xizang Jinhong lies in advanced manufacturing and the new energy sector, encompassing photovoltaics, chip design and manufacturing, consumer electronics, intelligent equipment, industrial automation, new energy, autonomous driving, and semiconductor equipment. The investment priorities of Xizang Green Industry Fund primarily focus on smart manufacturing, semiconductors, clean energy and technology, as well as upstream and downstream sectors in consumption and services.